{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:14:40Z","timestamp":1790813680752,"version":"4.1.0"},"reference-count":48,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2021,9,11]],"date-time":"2021-09-11T00:00:00Z","timestamp":1631318400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"F2G Ltd"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,12,24]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Invasive aspergillosis (IA) is an acute infection affecting patients who are immunocompromised, as a result of receiving chemotherapy for malignancy, or immunosuppressant agents for transplantation or autoimmune disease. Whilst criteria exist to define the probability of infection for clinical trials, there is little evidence in the literature or clinical guidelines on when to change antifungal treatment in patients who are receiving prophylaxis or treatment for IA. To try and address this significant gap, an advisory board of experts was convened to develop criteria for the management of IA for use in designing clinical trials, which could also be used in clinical practice. For primary treatment failure, a change in antifungal therapy should be made: (i) when mycological susceptibility testing identifies an organism from a confirmed site of infection, which is resistant to the antifungal given for primary therapy, or a resistance mutation is identified by molecular testing; (ii) at, or after, 8\u2009days of primary antifungal treatment if there is increasing serum galactomannan, or galactomannan positivity in serum, or bronchoalveolar lavage fluid when the antigen was previously undetectable, or there is sudden clinical deterioration, or a new clearly distinct site of infection is detected; and (iii) at, or after, 15\u2009days of primary antifungal treatment if the patient is clinically stable but with \u22652 serum galactomannan measurements persistently elevated compared with baseline or increasing, or if the original lesions on CT or other imaging, show progression by &amp;gt;25% in size in the context of no apparent change in immune status.<\/jats:p>","DOI":"10.1093\/jac\/dkab317","type":"journal-article","created":{"date-parts":[[2021,8,17]],"date-time":"2021-08-17T16:05:53Z","timestamp":1629216353000},"page":"16-23","source":"Crossref","is-referenced-by-count":37,"title":["When to change treatment of acute invasive aspergillosis: an expert viewpoint"],"prefix":"10.1093","volume":"77","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8443-314X","authenticated-orcid":false,"given":"Monica A","family":"Slavin","sequence":"first","affiliation":[{"name":"Department of Infectious Diseases, Peter MacCallum Cancer Centre, National Centre for Infections in Cancer, Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yee-Chun","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, National Taiwan University Hospital and College of Medicine, No. 7, Chung-Shan South Road, Taipei, 100, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Cordonnier","sequence":"additional","affiliation":[{"name":"Service d\u2019H\u00e9matologie clinique et de Th\u00e9rapie cellulaire, DMU Cancer, CHU Henri Mondor, 94000 Cr\u00e9teil, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9599-3137","authenticated-orcid":false,"given":"Oliver A","family":"Cornely","sequence":"additional","affiliation":[{"name":"University of Cologne, Faculty of Medicine and University Hospital Cologne, Department I of Internal Medicine, Excellence Center for Medical Mycology (ECMM), Cologne, Germany"},{"name":"Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD); Clinical Trials Centre Cologne (ZKS K\u00f6ln), Kerpener Str. 62, 50937 Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Cuenca-Estrella","sequence":"additional","affiliation":[{"name":"Instituto de Salud Carlos III, Ctra. Majadahonda-Pozuelo Km2, Majadahonda, Madrid 28220, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8521-335X","authenticated-orcid":false,"given":"J Peter","family":"Donnelly","sequence":"additional","affiliation":[{"name":"Nijmegen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1188-393X","authenticated-orcid":false,"given":"Andreas H","family":"Groll","sequence":"additional","affiliation":[{"name":"Infectious Disease Research Program, Center for Bone Marrow Transplantation and Department of Pediatric Hematology and Oncology, University Children\u2019s Hospital M\u00fcnster, Albert-Schweitzer-Campus 1, Building A1, 48149 M\u00fcnster, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Lortholary","sequence":"additional","affiliation":[{"name":"Paris University, Necker Pasteur Center for Infectious Diseases and Tropical Medicine, IHU Imagine, Necker Enfants Malades University Hospital, and Institute Pasteur, CNRS, Molecular Mycology Unit, APHP 149, rue de S\u00e8vres, 75015 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco M","family":"Marty","sequence":"additional","affiliation":[{"name":"Brigham and Women\u2019s Hospital, Boston, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4867-0014","authenticated-orcid":false,"given":"Marcio","family":"Nucci","sequence":"additional","affiliation":[{"name":"University Hospital, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John H","family":"Rex","sequence":"additional","affiliation":[{"name":"F2G Ltd, Lankro Way, Eccles, Manchester, M30 0LX, UK"},{"name":"McGovern Medical School at The University of Texas Health Science Center at Houston, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart J A","family":"Rijnders","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Section of Infectious Diseases and Department of Medical Microbiology and Infectious Diseases Erasmus MC, University Medical Center, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"III","given":"George R","family":"Thompson","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Infectious Diseases, 4150 V Street, Suite G500, Sacramento, CA 95817, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8600-9860","authenticated-orcid":false,"given":"Paul E","family":"Verweij","sequence":"additional","affiliation":[{"name":"Radboudumc-CWZ Center of Expertise for Mycology, Radboud University Nijmegen Medical Center, P.O. Box 9101, 6500 HB Nijmegen, The Netherlands"},{"name":"Center for Infectious Disease Research, Diagnostics and Laboratory Surveillance National Institute for Public Health and the Environment (RIVM), P.O. Box 1, 3720 BA Bilthoven, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P Lewis","family":"White","sequence":"additional","affiliation":[{"name":"Public Health Wales Mycology Reference Laboratory, University Hospital of Wales, Heath Park, Cardiff, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Hargreaves","sequence":"additional","affiliation":[{"name":"F2G Ltd, Lankro Way, Eccles, Manchester, M30 0LX, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Harvey","sequence":"additional","affiliation":[{"name":"F2G Ltd, Lankro Way, Eccles, Manchester, M30 0LX, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan A","family":"Maertens","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Immunology, and Transplantation, K.U. Leuven, Leuven, Belgium"},{"name":"Department of Hematology, U.Z. Leuven, Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,9,11]]},"reference":[{"key":"2022010520143267600_dkab317-B1","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1093\/cid\/ciz1008","article-title":"Revision and update of the consensus definitions of invasive fungal disease from the European organization for research and treatment of cancer and the Mycoses study group education and research consortium","volume":"71","author":"Donnelly","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2022010520143267600_dkab317-B2","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1056\/NEJMoa020191","article-title":"Voriconazole versus amphotericin B for primary therapy of IA","volume":"347","author":"Herbrecht","year":"2002","journal-title":"New Engl J Med"},{"key":"2022010520143267600_dkab317-B3","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1086\/514341","article-title":"Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial)","volume":"44","author":"Cornely","year":"2007","journal-title":"Clin Infect Dis"},{"key":"2022010520143267600_dkab317-B4","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/S0140-6736(15)01159-9","article-title":"Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial","volume":"387","author":"Maertens","year":"2016","journal-title":"Lancet"},{"key":"2022010520143267600_dkab317-B5","doi-asserted-by":"crossref","first-page":"81","DOI":"10.7326\/M13-2508","article-title":"Combination antifungal therapy for invasive aspergillosis: a randomized trial","volume":"162","author":"Marr","year":"2015","journal-title":"Ann Intern Med"},{"key":"2022010520143267600_dkab317-B6","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/S0140-6736(21)00219-1","article-title":"Posaconazole versus voriconazole for primary treatment of invasive aspergillosis: a phase 3, randomised, controlled, non-inferiority trial","volume":"397","author":"Maertens","year":"2021","journal-title":"Lancet"},{"key":"2022010520143267600_dkab317-B7","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1086\/423381","article-title":"Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy","volume":"39","author":"Maertens","year":"2004","journal-title":"Clin Infect Dis"},{"key":"2022010520143267600_dkab317-B8","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1086\/508774","article-title":"Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial","volume":"44","author":"Walsh","year":"2007","journal-title":"Clin Infect Dis"},{"key":"2022010520143267600_dkab317-B9","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1111\/myc.12274","article-title":"Randomised, multicentre trial of micafungin vs. an institutional standard regimen for salvage treatment of invasive aspergillosis","volume":"58","author":"Cornely","year":"2015","journal-title":"Mycoses"},{"key":"2022010520143267600_dkab317-B10","doi-asserted-by":"crossref","first-page":"2888","DOI":"10.1002\/cncr.22348","article-title":"Multicenter, noncomparative study of caspofungin in combination with other antifungals as salvage therapy in adults with invasive aspergillosis","volume":"107","author":"Maertens","year":"2006","journal-title":"Cancer"},{"key":"2022010520143267600_dkab317-B11","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1086\/590566","article-title":"Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria","volume":"47","author":"Segal","year":"2008","journal-title":"Clin Infect Dis"},{"key":"2022010520143267600_dkab317-B12","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1111\/myc.12769","article-title":"Isavuconazole treatment for rare fungal diseases and for invasive aspergillosis in patients with renal impairment: Challenges and lessons of the VITAL trial","volume":"61","author":"Perfect","year":"2018","journal-title":"Mycoses"},{"key":"2022010520143267600_dkab317-B13","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1200\/JCO.2001.19.1.253","article-title":"Increasing volume and changing characteristics of invasive pulmonary aspergillosis on sequential thoracic computed tomography scans in patients with neutropenia","volume":"19","author":"Caillot","year":"2001","journal-title":"J Clin Oncol"},{"key":"2022010520143267600_dkab317-B14","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1111\/myc.12960","article-title":"Defining breakthrough invasive fungal infection \u2013 position paper of the Mycoses Study Group Education and Research Consortium (MSG-ERC) and the European Confederation of Medical Mycology (ECMM)","volume":"62","author":"Cornely","year":"2019","journal-title":"Mycoses"},{"key":"2022010520143267600_dkab317-B15","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1007\/s00259-018-4062-8","article-title":"FDG PET\/CT imaging in detecting and guiding management of invasive fungal infections: a retrospective comparison to conventional CT imaging","volume":"46","author":"Douglas","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2022010520143267600_dkab317-B16","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1093\/cid\/ciy859","article-title":"Voriconazole resistance and mortality in invasive aspergillosis: a multicentre retrospective cohort study","volume":"68","author":"Lestrade","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2022010520143267600_dkab317-B17","doi-asserted-by":"crossref","first-page":"3528","DOI":"10.1093\/jac\/dkw323","article-title":"PCR-based detection of Aspergillus fumigatus Cyp51A mutations on bronchoalveolar lavage: a multicentre validation of the AsperGenius assay\u00ae in 201 patients with haematological disease suspected for invasive aspergillosis","volume":"71","author":"Chong","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"2022010520143267600_dkab317-B18","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.drup.2015.08.001","article-title":"International expert opinion on the management of infection caused by azole-resistant Aspergillus fumigatus","volume":"21\u201322","author":"Verweij","year":"2015","journal-title":"Drug Resist Updat"},{"key":"2022010520143267600_dkab317-B19","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.cmi.2018.01.002","article-title":"Diagnosis and management of aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline","volume":"24","author":"Ullman","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"2022010520143267600_dkab317-B20","doi-asserted-by":"crossref","first-page":"433","DOI":"10.3324\/haematol.2016.152900","article-title":"ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients","volume":"102","author":"Tissot","year":"2017","journal-title":"Haematologica"},{"key":"2022010520143267600_dkab317-B21","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/ciw326","article-title":"Practice guidelines for the diagnosis and management of aspergillosis: 2016 Update by the Infectious Diseases Society of America","volume":"63","author":"Patterson","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2022010520143267600_dkab317-B22","doi-asserted-by":"crossref","first-page":"2634","DOI":"10.1093\/jac\/dkw199","article-title":"A cohort study on breakthrough invasive fungal infections in high-risk patients receiving antifungal prophylaxis","volume":"71","author":"Biehl","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"2022010520143267600_dkab317-B23","first-page":"1621","article-title":"Breakthrough invasive mold infections in the hematology patient: current concepts and future directions","volume":"67","author":"Lionakis","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2022010520143267600_dkab317-B24","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1086\/657065","article-title":"Probable invasive aspergillosis without prespecified radiologic findings: proposal for inclusion of a new category of aspergillosis and implications for studying novel therapies","volume":"51","author":"Nucci","year":"2010","journal-title":"Clin Infect Dis"},{"key":"2022010520143267600_dkab317-B25","doi-asserted-by":"crossref","first-page":"113","DOI":"10.3390\/jof5040113","article-title":"Serial detection of circulating mucorales DNA in invasive mucormycosis: a retrospective multicenter evaluation","volume":"5","author":"Mercier","year":"2019","journal-title":"J Fungi (Basel)"},{"key":"2022010520143267600_dkab317-B26","doi-asserted-by":"crossref","first-page":"3858","DOI":"10.1182\/blood-2014-04-516211","article-title":"How we treat invasive fungal diseases in patients with acute leukemia: the importance of an individualized approach","volume":"124","author":"Nucci","year":"2014","journal-title":"Blood"},{"key":"2022010520143267600_dkab317-B27","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1007\/s00520-013-1844-1","article-title":"Substantially elevated C-reactive protein (CRP), together with low levels of procalcitonin (PCT), contributes to diagnosis of fungal infection in immunocompromised patients","volume":"21","author":"Markov\u00e1","year":"2013","journal-title":"Support Care Cancer"},{"key":"2022010520143267600_dkab317-B28","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1093\/cid\/civ885","article-title":"Azole resistance in Aspergillus fumigatus: can we retain the clinical use of mould-active antifungal azoles?","volume":"62","author":"Verweij","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2022010520143267600_dkab317-B29","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1128\/JCM.00520-17","article-title":"Culture-based methods and molecular tools for azole-resistant Aspergillus fumigatus detection in a Belgian University Hospital","volume":"55","author":"Montesinos","year":"2017","journal-title":"J Clin Microbiol"},{"key":"2022010520143267600_dkab317-B30","doi-asserted-by":"crossref","first-page":"2759","DOI":"10.1093\/jac\/dkz258","article-title":"Prevalence of voriconazole-resistant invasive aspergillosis and its impact on mortality in haematology patients","volume":"74","author":"Resendiz-Sharpe","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"2022010520143267600_dkab317-B31","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1111\/myc.12354","article-title":"Azole-resistant Aspergillus fumigatus isolates carrying TR34\/L98H mutations in Taiwan","volume":"58","author":"Wu","year":"2015","journal-title":"Mycoses"},{"key":"2022010520143267600_dkab317-B32","doi-asserted-by":"crossref","first-page":"157","DOI":"10.3201\/eid2201.150848","article-title":"Azole resistance of Aspergillus fumigatus in immunocompromised patients with invasive aspergillosis","volume":"22","author":"Alanio","year":"2016","journal-title":"Emerg Infect Dis"},{"key":"2022010520143267600_dkab317-B33","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.ijantimicag.2016.10.019","article-title":"Epidemiology of invasive aspergillosis and azole resistance in patients with acute leukaemia: the SEPIA study","volume":"49","author":"Koehler","year":"2017","journal-title":"Int J Antimicrob Agents"},{"key":"2022010520143267600_dkab317-B34","doi-asserted-by":"crossref","first-page":"e00358","DOI":"10.1128\/AAC.00358-18","article-title":"Molecular identification and susceptibility testing of molds isolated in a prospective surveillance of triazole resistance in Spain (FILPOP2 Study)","volume":"62","author":"Alastruey-Izquierdo","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2022010520143267600_dkab317-B35","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.3201\/eid2009.140142","article-title":"Passive surveillance for azole-resistant Aspergillus fumigatus, United States, 2011\u20132013","volume":"20","author":"Pham","year":"2014","journal-title":"Emerg Infect Dis"},{"key":"2022010520143267600_dkab317-B36","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.cmi.2018.09.008","article-title":"How to: EUCAST recommendations on the screening procedure E.Def 10.1 for the detection of azole resistance in Aspergillus fumigatus isolates using four-well azole-containing agar plates","volume":"25","author":"Guinea","year":"2019","journal-title":"Clin Microbiol Infect"},{"key":"2022010520143267600_dkab317-B37","doi-asserted-by":"crossref","first-page":"3325","DOI":"10.1093\/jac\/dkx319","article-title":"Multicentre validation of 4-well azole agar plates as a screening method for detection of clinically relevant azole-resistant Aspergillus fumigatus","volume":"72","author":"Arendrup","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"2022010520143267600_dkab317-B38","doi-asserted-by":"crossref","first-page":"ofz176","DOI":"10.1093\/ofid\/ofz176","article-title":"Incidence and risk factors for breakthrough invasive mold infections in acute myeloid leukemia patients receiving remission induction chemotherapy","volume":"6","author":"Patel","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"2022010520143267600_dkab317-B39","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.1128\/JCM.00411-17","article-title":"Analytical and clinical evaluation of the PathoNostics AsperGenius assay for detection of invasive aspergillosis and resistance to azole antifungal drugs directly from plasma samples","volume":"55","author":"White","year":"2017","journal-title":"J Clin Microbiol"},{"key":"2022010520143267600_dkab317-B40","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1093\/jac\/dks402","article-title":"Efficacy and pharmacodynamics of voriconazole combined with anidulafungin in azole-resistant invasive aspergillosis","volume":"68","author":"Seyedmousavi","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"2022010520143267600_dkab317-B41"},{"key":"2022010520143267600_dkab317-B42","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1182\/blood-2017-11-818286","article-title":"Early-onset invasive aspergillosis and other fungal infections in patients treated with ibrutinib","volume":"131","author":"Ghez","year":"2018","journal-title":"Blood"},{"key":"2022010520143267600_dkab317-B43","doi-asserted-by":"crossref","first-page":"S53","DOI":"10.1016\/j.cmi.2018.02.009","article-title":"ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Intracellular signaling pathways: tyrosine kinase and mTOR inhibitors)","volume":"24 Suppl 2","author":"Reinwald","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"2022010520143267600_dkab317-B44","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.cmi.2019.01.016","article-title":"Concurrent cerebral aspergillosis and abdominal mucormycosis during ibrutinib therapy for chronic lymphocytic leukaemia","volume":"25","author":"Pouvaret","year":"2019","journal-title":"Clin Microbiol Infect"},{"key":"2022010520143267600_dkab317-B45","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1080\/10428194.2018.1485913","article-title":"Isavuconazole for the treatment of invasive fungal disease in patients receiving ibrutinib","volume":"60","author":"Cummins","year":"2019","journal-title":"Leuk Lymphoma"},{"key":"2022010520143267600_dkab317-B46","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1002\/jcph.858","article-title":"Quantitative prediction of the effect of CYP3A inhibitors and inducers on venetoclax pharmacokinetics using a physiologically based pharmacokinetic model","volume":"57","author":"Freise","year":"2017","journal-title":"J Clin Pharmacol"},{"key":"2022010520143267600_dkab317-B47","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s10928-017-9509-1","article-title":"Prognostic value of galactomannan: current evidence for monitoring response to antifungal therapy in patients with invasive aspergillosis","volume":"44","author":"Kovanda","year":"2017","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"2022010520143267600_dkab317-B48","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1128\/jcm.35.6.1353-1360.1997","article-title":"Detection and Identification of Fungal Pathogens in Blood by Using Molecular Probes","volume":"35","author":"Einsele","year":"1997","journal-title":"J Clin Microbiol"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/77\/1\/16\/41931260\/dkab317.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/77\/1\/16\/41931260\/dkab317.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,7]],"date-time":"2023-11-07T08:50:22Z","timestamp":1699347022000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/77\/1\/16\/6368907"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,11]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,9,11]]},"published-print":{"date-parts":[[2021,12,24]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkab317","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.740792673.793588569","asserted-by":"object"}]},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,1,1]]},"published":{"date-parts":[[2021,9,11]]}}}